Geode Capital Management
CSTL icon

Geode Capital Management’s Castle Biosciences CSTL Stock Holding History

Geode Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Buy
795,912
+67,812
+9% +$1.51M ﹤0.01% 2184
2026
Q1 		$17.9M Buy
728,100
+13,187
+2% +$432K ﹤0.01% 2054
2025
Q4 		$27.8M Buy
714,913
+16,303
+2% +$526K ﹤0.01% 1835
2025
Q3 		$15.9M Buy
698,610
+8,684
+1% +$176K ﹤0.01% 2123
2025
Q2 		$14.1M Buy
689,926
+40,073
+6% +$742K ﹤0.01% 2142
2025
Q1 		$13M Buy
649,853
+21,657
+3% +$536K ﹤0.01% 2132
2024
Q4 		$16.7M Buy
628,196
+3,513
+0.6% +$107K ﹤0.01% 2062
2024
Q3 		$17.8M Buy
624,683
+7,004
+1% +$178K ﹤0.01% 2036
2024
Q2 		$13.4M Buy
617,679
+39,145
+7% +$872K ﹤0.01% 2148
2024
Q1 		$12.8M Buy
578,534
+12,419
+2% +$270K ﹤0.01% 2172
2023
Q4 		$12.2M Buy
566,115
+29,879
+6% +$526K ﹤0.01% 2223
2023
Q3 		$9.06M Buy
536,236
+38,552
+8% +$674K ﹤0.01% 2332
2023
Q2 		$6.83M Buy
497,684
+12,730
+3% +$258K ﹤0.01% 2525
2023
Q1 		$11M Buy
484,954
+19,287
+4% +$471K ﹤0.01% 2205
2022
Q4 		$11M Buy
465,667
+20,004
+4% +$464K ﹤0.01% 2205
2022
Q3 		$11.6M Buy
445,663
+15,107
+4% +$424K ﹤0.01% 2122
2022
Q2 		$9.45M Buy
430,556
+29,544
+7% +$687K ﹤0.01% 2290
2022
Q1 		$18M Buy
401,012
+15,271
+4% +$631K ﹤0.01% 1967
2021
Q4 		$16.5M Buy
385,741
+20,373
+6% +$1.06M ﹤0.01% 2087
2021
Q3 		$24.3M Buy
365,368
+25,293
+7% +$1.78M ﹤0.01% 1817
2021
Q2 		$24.9M Buy
340,075
+59,033
+21% +$3.9M ﹤0.01% 1817
2021
Q1 		$19.2M Buy
281,042
+48,005
+21% +$3.61M ﹤0.01% 1904
2020
Q4 		$15.6M Buy
233,037
+26,280
+13% +$1.42M ﹤0.01% 1876
2020
Q3 		$10.6M Buy
206,757
+94,912
+85% +$4.22M ﹤0.01% 1903
2020
Q2 		$4.21M Buy
111,845
+6,209
+6% +$212K ﹤0.01% 2432
2020
Q1 		$3.15M Buy
105,636
+46,901
+80% +$1.42M ﹤0.01% 2423
2019
Q4 		$2.02M Buy
58,735
+20,804
+55% +$509K ﹤0.01% 3004
2019
Q3 		$686K Buy
+37,931
New +$841K ﹤0.01% 3368

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Geode Capital Management's CSTL Position: Q2 2026 in Review

Geode Capital Management increased its Castle Biosciences (CSTL) stake by 9.3% in Q2 2026, buying an estimated $1.51M and bringing the position to 795,912 shares worth $19M. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

Geode Capital Management first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $27.8M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Geode Capital Management held 795,912 shares of Castle Biosciences worth $19M as of Q2 2026.
  • Geode Capital Management bought 67,812 Castle Biosciences shares in Q2 2026, an estimated $1.51M.
  • Castle Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2184 holding.
  • Geode Capital Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Geode Capital Management's Castle Biosciences position peaked at $27.8M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.